ABVC BioPharma (NASDAQ:ABVC) & Rhythm Pharmaceuticals (NASDAQ:RYTM) Head-To-Head Review

ABVC BioPharma (NASDAQ:ABVC) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, analyst recommendations, institutional ownership and earnings.

Valuation & Earnings

This table compares ABVC BioPharma and Rhythm Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ABVC BioPharma	$150,000.00	47.94	-$10.52 million	($0.86)	-0.64
Rhythm Pharmaceuticals	$112.53 million	30.68	-$184.68 million	($4.33)	-12.97

ABVC BioPharma has higher earnings, but lower revenue than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than ABVC BioPharma, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations and price targets for ABVC BioPharma and Rhythm Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ABVC BioPharma	0	0	0	0	0.00
Rhythm Pharmaceuticals	0	1	10	0	2.91

Rhythm Pharmaceuticals has a consensus target price of $68.09, suggesting a potential upside of 21.22%. Given Rhythm Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe Rhythm Pharmaceuticals is more favorable than ABVC BioPharma.

Institutional and Insider Ownership

11.4% of ABVC BioPharma shares are held by institutional investors. 11.9% of ABVC BioPharma shares are held by insiders. Comparatively, 5.6% of Rhythm Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares ABVC BioPharma and Rhythm Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ABVC BioPharma	-1,619.65%	-104.94%	-56.81%
Rhythm Pharmaceuticals	-230.07%	-367.36%	-77.47%

Risk & Volatility

ABVC BioPharma has a beta of 0.71, suggesting that its share price is 29% less volatile than the S&P 500. Comparatively, Rhythm Pharmaceuticals has a beta of 2.16, suggesting that its share price is 116% more volatile than the S&P 500.

Summary

ABVC BioPharma beats Rhythm Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

About ABVC BioPharma

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.